Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Ultrasound-Guided Serratus Anterior Plane Block for Additional Pain Relief After Lung Surgery

Phase 2

Completed

Conditions: Thoracic Surgery

Interventions: Procedure: Serratus anterior plane block
Procedure: Sham serratus anterior plane block

First Posted Date: 2020-01-23

Last Posted Date: 2024-11-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 93

Registration Number: NCT04238455

Locations: 🇺🇸
Memorial Sloan Kettering Nassau (Consent only), Uniondale, New York, United States
🇺🇸
Memorial Sloan Kettering Monmouth (Consent only), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Commack (Consent Only), Commack, New York, United States

and more 3 locations

Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer

Phase 2

Active, not recruiting

Conditions: Thyroid Cancer
BRAF Gene Mutation
Anaplastic Thyroid Cancer
BRAF Mutation-Related Tumors

Interventions: Drug: Dabrafenib
Drug: Trametinib

First Posted Date: 2020-01-23

Last Posted Date: 2024-12-02

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 16

Registration Number: NCT04238624

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States

and more 4 locations

Studying a New Piece of Equipment That Can Help Plan Radiation Therapy of the Spine

Not Applicable

Active, not recruiting

Conditions: Thoracic Neoplasms
Spine Metastases
Thoracic Cancer
Spine Cancer
Thoracic Diseases
Spine Disease

Interventions: Diagnostic Test: MRI with custom MRI spine coil

First Posted Date: 2020-01-14

Last Posted Date: 2024-06-26

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 9

Registration Number: NCT04227717

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission

Recruiting

Conditions: Plasma Cell Myeloma

Interventions: Other: Cessation of continuous matinenace therapy

First Posted Date: 2020-01-09

Last Posted Date: 2024-08-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 50

Registration Number: NCT04221178

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Nassau, Uniondale, New York, United States

and more 4 locations

A Study of the Use of Text Message Reminders to Take Palbociclib

Not Applicable

Active, not recruiting

Conditions: Breast Cancer

Interventions: Other: OhMD APP
Other: Paper Drug Diary

First Posted Date: 2020-01-02

Last Posted Date: 2024-01-22

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 45

Registration Number: NCT04216576

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States

and more 4 locations

A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma

Phase 3

Active, not recruiting

Conditions: Marginal Zone Lymphoma

Interventions: Drug: Ibrutinib
Drug: Rituximab
Other: Placebo

First Posted Date: 2019-12-26

Last Posted Date: 2024-07-23

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 23

Registration Number: NCT04212013

Locations: 🇺🇸
Memorial Sloan Kettering Nassau, Uniondale, New York, United States
🇺🇸
George Washington Cancer Center, Washington, District of Columbia, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

and more 7 locations

Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers

Phase 2

Recruiting

Conditions: Adenoid Cystic Carcinoma
Salivary Gland Cancer

Interventions: Drug: Lenvatinib
Drug: Pembrolizumab

First Posted Date: 2019-12-24

Last Posted Date: 2024-08-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 64

Registration Number: NCT04209660

Locations: 🇺🇸
Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey, United States
🇺🇸
Baptist Alliance MCI, Miami, Florida, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States

and more 5 locations

Glucose Monitoring to Predict and Treat High Glucose Levels After Steroid Treatment

Completed

Conditions: Pancreatic Cancer
Breast Cancer
Diabetes
Pre Diabetes

First Posted Date: 2019-12-24

Last Posted Date: 2023-11-01

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 3

Registration Number: NCT04210128

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy

Active, not recruiting

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Stage III Ovarian Cancer
Stage IV Ovarian Cancer
Primary Peritoneal Carcinoma
Fallopian Tube Carcinoma

Interventions: Other: Prehabilitation

First Posted Date: 2019-12-19

Last Posted Date: 2025-01-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 22

Registration Number: NCT04204811

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56

Recruiting

Conditions: Small Cell Lung Cancer
Small Cell Lung Carcinoma

Interventions: Drug: 89Zr-DFO-SC16.56
Drug: SC16.56, Phase I, Cohort 2
Drug: SC16.56, Phase II
Drug: SC16.56, Phase I, Cohort 3

First Posted Date: 2019-12-16

Last Posted Date: 2024-08-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 41

Registration Number: NCT04199741

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy